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al.), whereas the cytoplasmic domain of 
CD3ζ has two serines within the analo-
gous region (Sigalov et al., 2006). Inter-
estingly, the serine/threonine kinase 
GRK2 has been shown to constitutively 
associate with the polybasic region of 
the CD3ε cytoplasmic domain (DeFord-
Watts et al., 2007). A mechanical force 
or multimerization could be invoked as 
the causative agent of the serine/threo-
nine phosphorylation. Such a mecha-
nism is appealing because exposing the 
CD3ε and CD3ζ cytoplasmic domains 
for phosphorylation would be intrin-
sic to the TCR-CD3 complex that is 
engaged. Scalable signaling might also 
be regulated via serine/threonine phos-
phorylation within the ITAMs, as has 
been shown to regulate B cell receptor 
signaling (Muller et al., 2000). Clearly 
several more pieces need to be put in 
place before the TCR signaling puzzle 
is solved, but the study by Xu and col-
leagues is an important step forward.
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A major challenge to understanding how cells work together in the central nervous system (CNS) 
is the heterogeneous cellular composition of the brain. In this issue, Heiman et al. (2008) and Doyle 
et al. (2008) introduce a new strategy (TRAP) that enables the profiling of translated mRNAs in 
specific CNS cell populations without the need for purifying cells to homogeneity.Understanding how myriad different 
cell types in the brain communicate to 
give rise to cognition and perception is 
the central challenge of neurobiology 
today. One powerful method for helping 
to understand how cells communicate is 
genome-wide gene profiling. However, 
because of the large degree of cellular 
heterogeneity, the mammalian central 
nervous system (CNS) poses particular 
challenges for gene profiling. Not only is 
the CNS composed of multiple distinct 
and often ill-defined regions, but each 
of these regions also consists of mul-
tiple cell types, many of which are rare 
and contribute only a small fraction of 
mRNAs to the total pool of transcripts. 
Although ambitious projects such as 
the Allen and GENSAT brain atlases 596 Cell 135, November 14, 2008 ©2008 Elthat map gene expression patterns in 
the brain have provided invaluable infor-
mation about the spatial expression of 
large numbers of genes within the CNS, 
the exact identities of the cells express-
ing the genes are not always evident. 
Moreover, these databases cannot 
hope to be comprehensive in captur-
ing the gene expression changes that 
occur in different CNS cell populations 
in various disease states or experimen-
tal scenarios. A variety of clever strate-
gies have been successfully applied to 
profile gene expression using mRNAs 
isolated from highly purified populations 
of specific CNS cell types. These meth-
ods have taken advantage of transgenic 
mice expressing fluorescent proteins in 
the specific CNS population of interest sevier Inc.or the use of retrograde tracer marking 
to label specific populations (Arlotta et 
al., 2005; Sugino et al., 2006; Lobo et al., 
2006; Dugas et al., 2008; Cahoy et al., 
2008). Although these techniques have 
yielded much useful information, they 
share several potential disadvantages, 
including the concern that the act of iso-
lating the cells may alter their transcrip-
tional profile. Moreover, depending on 
the cell type in question, isolation of spe-
cific cells to a suitable level of homoge-
neity can be cumbersome, thus making 
repeated or parallel cell type isolations 
to assess transcriptional changes under 
different experimental conditions unfea-
sible. In this issue, two complementary 
studies (Heiman et al., 2008; Doyle et 
al., 2008) present an elegant new tech-
nique, called translating ribosome affin-
ity purification (TRAP), for determining 
the translational profiles of specific cell 
types within the brain.
The GENSAT Project (http://www.
gensat.org/) database contains a gene 
expression atlas of the central nervous 
system of the mouse based on bacte-
rial artificial chromosomes (BACs). BAC 
mouse lines are made with BAC trans-
genic vectors in which the endogenous 
protein coding sequences of a gene 
of interest have been replaced by the 
sequence for enhanced green fluores-
cent protein (EGFP), thus putting EGFP 
under the control of the normal regula-
tory sequences of the gene of inter-
est. This EGFP reporter is integrated in 
the mouse, and EGFP is expressed in 
the same spatial and temporal pattern 
as the endogenous protein of interest 
(Gong et al., 2003; Heintz, 2004). Heiman 
et al. and Doyle et al. have now created 
new bacTRAP mouse lines in which the 
BAC vectors all encode an EGFP-tagged 
L10a ribosomal protein within specific 
CNS cell types. Affinity purification of 
this EGFP-L10a fusion protein with anti-
EGFP antibodies thus yields the ribo-
some and its associated mRNAs, allow-
ing the isolation of transcripts from the 
EGFP-L10a-expressing cell type of inter-
est (Figure 1). This is an enhancement of 
a technique previously used in the worm 
Caenorhabditis elegans in which the 
targeted expression of epitope-tagged 
poly(A)-binding protein enabled purifi-
cation of bound RNA from cell types of 
interest for gene profiling (e.g., Roy et al., 
2002).
As a demonstration of what can be 
done with this new method, Heiman et al. 
generated BAC mouse lines expressing 
the EGFP-L10a ribosomal protein from the 
D1 or D2 dopamine receptor promoters in 
striatonigral and striatopallidal medium 
spiny neurons (MSNs), respectively. The 
immunoaffinity-purified mRNAs from 
each mouse line not only were enriched 
for almost all of the previously reported 
differentially expressed MSN mark-
ers, but also revealed numerous new 
striatopallidal- or striatonigral-enriched 
transcripts. Importantly, Heiman et al. 
also demonstrated that this technique 
is sufficiently sensitive to detect transla-
tional changes in cell populations after 
an experimental manipulation (cocaine administration). The two neuronal popu-
lations responded differently to cocaine 
administration, leading to new experi-
mentally testable predictions for molec-
ular responses to this molecule. Doyle et 
al. further extended the use of the tech-
nique by reporting the transgene expres-
sion patterns for the four EGFP-L10a 
bacTRAP mouse lines described in the 
Heiman et al. study. They also describe 
an additional 12 bacTRAP mouse lines 
targeting the EGFP-L10a ribosomal trans-
gene to a variety of different neuronal and 
glial populations. Using these bacTRAP 
transgenic mouse lines and dissection of 
different CNS regions, Doyle et al. report 
the translational profiles of 24 CNS cell 
types, including astrocytes, oligodendro-
cytes, and different types of neurons.
The TRAP approach offers several 
advantages that distinguish it from cur-
rent methods. The most obvious of these 
may be its relative experimental simplic-
ity, as it makes laborious and technically 
challenging cell isolation procedures 
unnecessary. Even relatively rare cell 
types such as the unipolar brush cells 
of the cerebellum can now be readily 
studied. In addition, this method greatly 
enhances the ability to generate repro-
ducible results. Doyle et al. demonstrate 
that results from different mouse lines 
with the same BAC transgene are highly 
consistent. Needless to say, selection of 
the appropriate bacTRAP line that cor-
rectly represents the cell type of inter-
est is essential. Finally, the TRAP tech-
nique makes it possible to profile the 
gene expression patterns of specific cell 
types in adult mouse neural tissues. In 
contrast, fluorescence-activated cell 
sorting (FACS)—a method currently used 
to purify the same cell types—generally 
requires the use of early postnatal mice. 
TRAP provides an exciting step forward 
because it means that specific neural cell 
types can now be profiled in adult mouse 
models of neurological disease.
An intriguing aspect to the TRAP 
approach is that it targets translated 
RNAs rather than total mRNAs and is 
thus possibly a better reflection of pro-
tein expression. Through comparison 
of TRAP profiles with profiles obtained 
with total mRNAs, it may be possible to 
identify mRNAs that are under strong 
translational control. That said, at least 
some supposedly untranslated mRNAs, Cell 135, figure 1. the tRAP technique
BAC transgenic (bacTRAP) mice express EGFP-
tagged L10a ribosomal protein (green) in targeted 
brain cell populations. Target tissues are dissected 
from the brain and lysed, and the translating ribo-
somes attached to mRNAs (polysomes) are sta-
bilized with cycloheximide. Polysomes are then 
affinity purified with EGFP antibody-coated mag-
netic beads, enabling enrichment of polysomes 
from the cells of interest expressing the fusion 
protein. Affinity-purified mRNA levels are com-
pared to the unbound mRNAs by gene profiling 
to assess enrichment of genes specific to the cell 
type of interest.November 14, 2008 ©2008 Elsevier Inc. 597
such as those encoding the neuronal 
protein Gap43 and the glial prion pro-
tein Prnp, are highly represented in the 
TRAP data sets, suggesting that some 
translationally inhibited mRNAs remain 
bound to ribosomes. On the other hand, 
noncoding RNAs such as Gtl2 that are 
never translated are not detectable in 
the TRAP-bound samples, although 
they can be detected by standard gene 
profiling methods. One potential caveat 
of the TRAP technique is that during 
preparation of the tissue lysate (Fig-
ure 1), mixing of mRNAs between all 
of the cell types occurs, providing an 
opportunity for mRNAs from unwanted 
cell types to bind to the EGFP-L10a-
tagged ribosomes. Fortunately, use of 
conditions that stabilize mRNA binding 
to ribosomes minimizes this problem. 
Indeed, for the most part, the TRAP 
gene profiles for glia are strikingly 
similar to those previously elucidated 
for purified astrocytes and oligoden-
drocytes (Cahoy et al., 2008; B.A.B., 598 Cell 135, November 14, 2008 ©2008 Elunpublished data). One interesting dif-
ference resides in the relative levels of 
expressed mRNAs, which vary widely 
between the two methods. It is not yet 
clear whether this difference reflects 
physiological differences in the sam-
ples used (for example, the age of the 
CNS tissue) or whether it reflects vari-
ables in experimental conditions, such 
as the efficiency of affinity purification. 
Regardless, the possibilities offered by 
the TRAP approach seem limitless, as it 
can theoretically be applied to any cell 
type, in any tissue, under any condition. 
In particular, the applications of TRAP 
analysis for understanding neurologi-
cal disease will be an exciting area for 
future exploration.
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